阿斯利康在与百时美施贵宝进行4000亿美元合并谈判的报道后股价下跌7%

2026-08-03 · cnbc.com

据《金融时报》周日报道，这两家公司近几个月一直在讨论潜在的合并事宜。

AstraZeneca shares dropped as much as 7% after a report that the U.K.'s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb over a megadeal that,...